Lélia Delamarre holds a PhD in Virology from Université Pierre et Marie Curie in France. After completing her postdoctoral training at Yale University, she joined the Department of Cancer Immunology at biotech company Genentech in California. Her research group explores novel approaches to expand anti-tumor T cell responses through priming. A recent focus has been the identification of the tumor antigens that shape immune responses to cancer. Her group contributed to the identification of cancer-specific mutations, also called neoantigens, as the drivers of protective T cell responses against cancer. This discovery provides the opportunity to develop novel approaches, including vaccines, to selectively target cancer neoantigens.